GlassScriptPhysician profile
Shea Robert Idlewine
NPI 1427694983
$3,817.79
in general payments reported to CMS, 2019-2025
34 companies · $1,423 in 2025
The $1,423 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $65.72 · 2022: $355 · 2023: $503 · 2024: $1,471 · 2025: $1,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,397.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $559.95 | 2022-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $369.14 | 2023-2025 | Farxiga, Brilinta, Wainua |
| Novartis Pharmaceuticals Corporation | $363.83 | 2022-2025 | |
| Lexicon Pharmaceuticals, INC. | $333.13 | 2023-2024 | Inpefa |
| Supernus Pharmaceuticals, INC. | $328.01 | 2024 | Qelbree |
| Boston Scientific Corporation | $326.67 | 2024-2025 | Watchman Flx, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.80 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $189.19 | 2024-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $135.26 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $121.83 | 2022-2024 | Xarelto |
| Corcept Therapeutics | $117.81 | 2024-2025 | Korlym |
| Abbvie INC. | $92.85 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.91 | 2022-2025 | |
| Amgen INC. | $67.42 | 2022-2025 | |
| Lilly USA, LLC | $44.73 | 2022-2025 | Mounjaro, Zepbound |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $41.92 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Paratek Pharmaceuticals, INC. | $41.19 | 2022 | |
| Madrigal Pharmaceuticals | $34.71 | 2025 | Rezdiffra |
| Axsome Therapeutics, INC. | $33.80 | 2022-2023 | Auvelity |
| Regeneron Healthcare Solutions, INC. | $32.19 | 2022-2023 | Evkeeza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.35 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $28.05 | 2023 | Arcalyst |
| Biohaven Pharmaceutical Holding Company LTD. | $26.67 | 2022 | |
| Sanofi Pasteur INC. | $26.14 | 2021-2022 | |
| Coopersurgical, INC. | $26.06 | 2021 | |
| Cvrx, INC. | $25.86 | 2023 | Barostim Neo System |
| Otsuka America Pharmaceutical, INC. | $25.01 | 2022-2023 | Rexulti |
| Kestra Medical Technology Services, INC. | $24.87 | 2024 | Assure Wcd |
| Bridgebio Pharma, INC. | $18.14 | 2025 | Attruby |
| Exact Sciences Corporation | $17.90 | 2023 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $17.62 | 2024 | Eliquis |
| Esperion Therapeutics, INC. | $14.94 | 2025 | Nexletol |
| Mylan Specialty L.P. | $14.72 | 2022 | |
| Amarin Pharma, INC. | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shea Idlewine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.